MAM
ABBV icon

McLaughlin Asset Management’s AbbVie ABBV Stock Holding History

McLaughlin Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$932K Sell
3,705
-253
-6% -$54.4K 0.64% 45
2026
Q1 		$861K Sell
3,958
-105
-3% -$23.3K 0.82% 47
2025
Q4 		$928K Buy
+4,063
New +$926K 0.83% 42

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

McLaughlin Asset Management's ABBV Position: Q2 2026 in Review

McLaughlin Asset Management reduced its AbbVie (ABBV) stake by 6.4% in Q2 2026, selling an estimated $54.4K and leaving 3,705 shares worth $932K. The position accounts for 0.64% of the portfolio, ranked #45.

McLaughlin Asset Management first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • McLaughlin Asset Management held 3,705 shares of AbbVie worth $932K as of Q2 2026.
  • McLaughlin Asset Management sold 253 AbbVie shares in Q2 2026, an estimated $54.4K.
  • AbbVie made up 0.64% of McLaughlin Asset Management's portfolio in Q2 2026, its #45 holding.
  • McLaughlin Asset Management first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on McLaughlin Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.